TNP-470: an angiogenesis inhibitor in clinical development for cancer.
about
Effect of nitroxoline on angiogenesis and growth of human bladder cancerAn orally delivered small-molecule formulation with antiangiogenic and anticancer activityPyridinylpyrimidines selectively inhibit human methionine aminopeptidase-1Pyridinylquinazolines Selectively Inhibit Human Methionine Aminopeptidase-1 in CellsPhosphatase inhibitors with anti-angiogenic effect in vitroMetronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts.Angiogenesis inhibitors: current strategies and future prospects.Adipose tissue mass can be regulated through the vasculature.Anti-angiogenic treatment strategies for the therapy of endometriosis.Mutations at the S1 sites of methionine aminopeptidases from Escherichia coli and Homo sapiens reveal the residues critical for substrate specificity.Exploring the role of mitochondrial UQCRB in angiogenesis using small molecules.Targeted gene disruption of methionine aminopeptidase 2 results in an embryonic gastrulation defect and endothelial cell growth arrestCellular actions and signaling by endostatin.In vitro and in vivo evaluation of the anti-angiogenic actions of 4-hydroxybenzyl alcohol.Tumor angiogenesis as a target for dietary cancer preventionDisruption of Wnt planar cell polarity signaling by aberrant accumulation of the MetAP-2 substrate Rab37.Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay.Effects of TNP-470 on proliferation and apoptosis in human colon cancer xenografts in nude mice.Angiogenesis is required for stress fracture healing in rats.The fumagillin biosynthetic gene cluster in Aspergillus fumigatus encodes a cryptic terpene cyclase involved in the formation of β-trans-bergamoteneTargeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain.A single amino acid residue defines the difference in ovalicin sensitivity between type I and II methionine aminopeptidasesShared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model.Mutation of H63 and its catalytic affect on the methionine aminopeptidase from Escherichia coli.Novel technologies for antiangiogenic drug delivery in the brain.Generation of complexity in fungal terpene biosynthesis: discovery of a multifunctional cytochrome P450 in the fumagillin pathway.Ariadne's ChemEffect and Pathway Studio knowledge base.Anticancer and antifungal compounds from Aspergillus, Penicillium and other filamentous fungi.Terpenoids from the Marine-Derived Fungus Aspergillus fumigatus YK-7.2,5-diketopiperazines from the marine-derived fungus Aspergillus fumigatus YK-7.Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances.Methionine aminopeptidase 2 over-expressed in cholangiocarcinoma: potential for drug target.NC2213: a novel methionine aminopeptidase 2 inhibitor in human colon cancer HT29 cells.Computational approaches for drug repositioning and combination therapy design.TNP-470 inhibits 7,12-dimethylbenz[a]anthracene-induced mammary tumor formation when administered before the formation of carcinoma in situ but is not additive with tamoxifen.Synthesis and SAR studies of praziquantel derivatives with activity against Schistosoma japonicum.Anti-angiogenic drug loaded liposomes: Nanotherapy for early atherosclerotic lesions in mice.Effects of Angiogenesis Inhibitors on Vascular Network Formation by Human Endothelial and Melanoma Cells
P2860
Q24629326-F3BB2AFE-F286-4607-B171-6300ECFFCF4EQ24649290-66FD6123-CB07-4181-A964-FC315C9E310FQ27676869-7F11BB04-76CB-448E-AB13-B5F540C26114Q27677949-5D016E35-77A8-45BB-B0C1-67FB610CB1B7Q33588814-B0637842-D648-4552-9BC7-3FCD20B58533Q33918981-2C1E0BF5-16D4-4EB0-9292-74563B118034Q34056376-34ABCFA5-F147-4AD8-B9AA-62DFE83A5467Q34075818-B11046FD-7B70-46EB-B2BC-957DA69FAE5FQ34283036-824BA234-F3C7-4B1A-AEF7-B2DFB46763DFQ34300043-87AF27B6-40A3-4788-9F00-AAC9F5048540Q34332044-851F2867-5E6F-49D4-8CAD-4128DCD2049FQ34687606-7E54ED8F-EDB3-441F-80D6-DE399A1CD398Q35008096-E6469BBF-12D7-4502-A33B-8623E50DE4ABQ35036197-B42A9FED-C27D-4DFE-80B1-620FB6EA2639Q35250910-32F1CC2F-CDDB-49B0-B44A-C833ADAF8C39Q35491403-CC274539-CB5A-4FCF-A837-5F09730CD090Q35749086-699E29DD-7838-4E5E-8827-74D592134329Q36178323-8E36304E-4D78-4AC3-B4E7-1C0C1BB3F428Q36442977-3551119E-7768-488B-8C15-EB5C9C570916Q36840486-786CB314-7242-4856-B0B9-669193A79CDAQ36890872-D5CD544E-77CE-4E0E-8427-B93F2165A8C8Q36915728-CF086803-A4BF-46B8-AD64-AAF7A4327DE1Q37117375-ADC3542A-DD58-4974-820A-2478E16084CBQ37172110-6633885D-F432-42F3-93AC-2715AEE34F3DQ37186246-88E9C5A8-B871-4E39-AA8E-599307F19E32Q37701669-6223264C-6412-4C1F-B4DD-964150630146Q38088349-E5D0BC7D-BF42-4F8F-89C4-ECE19FF01C9EQ38142539-82730F6B-43EB-486A-BD14-8F67A07BFBDBQ38806698-9C1C6F61-F9E6-4E7B-A44B-0B8CC8389F04Q39394580-56DF57D9-2A21-4B32-AA79-B6BE17486CBBQ39571989-69ED01B2-FC62-4CA0-AF4E-D029591B54BFQ40142771-F0641B73-D012-4DF5-896B-56797ABC66AFQ42249201-1234DBC3-54CC-4F42-9279-E4B0FC4D37CFQ43015433-B76CD820-6161-4818-816A-E4516D0BA30AQ44513289-B11E8D98-0AD0-4DB0-A45A-E01DE95E902DQ46081944-1BA33112-48D7-468B-A167-655D86A43EDAQ48235332-A348E3FA-3D1A-4650-B89B-34E0316226FAQ57373805-06638FC0-1978-45B4-B50C-5F6A11D30DBD
P2860
TNP-470: an angiogenesis inhibitor in clinical development for cancer.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
TNP-470: an angiogenesis inhibitor in clinical development for cancer.
@ast
TNP-470: an angiogenesis inhibitor in clinical development for cancer.
@en
TNP-470: an angiogenesis inhibitor in clinical development for cancer.
@nl
type
label
TNP-470: an angiogenesis inhibitor in clinical development for cancer.
@ast
TNP-470: an angiogenesis inhibitor in clinical development for cancer.
@en
TNP-470: an angiogenesis inhibitor in clinical development for cancer.
@nl
prefLabel
TNP-470: an angiogenesis inhibitor in clinical development for cancer.
@ast
TNP-470: an angiogenesis inhibitor in clinical development for cancer.
@en
TNP-470: an angiogenesis inhibitor in clinical development for cancer.
@nl
P2860
P1476
TNP-470: an angiogenesis inhibitor in clinical development for cancer.
@en
P2093
P2860
P304
P356
10.1517/13543784.9.6.1383
P407
P577
2000-06-01T00:00:00Z